In the Weight-Loss Wars, Novo’s Obesity Pill Is Pulling Way Ahead of Lilly’s

The launch of weight-loss pills is the hottest battle in pharma. So far, Eli Lilly LLY 1.15%increase; up pointing triangle is losing to rival Novo Nordisk NOVO.B 1.59%increase; up pointing triangle.

Since its obesity pill Foundayo hit the market in April, Lilly has captured about 11% of the prescription volume for new pills, according to the latest weekly data. Novo Nordisk’s Wegovy pill, which launched in January, commands the rest.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8